ibtrozi
Ibtrozi (Taletrectinib Adipate) is a kinase inhibitor used to treat Non-Small-Cell Lung Carcinoma.
Taletrectinib Adipate · by Nuvation
Key facts
- Active ingredient
- Taletrectinib Adipate
- Drug class
- Kinase Inhibitor
- Form
- Capsule
- Strength
- Taletrectinib Adipate EQ 200MG Base
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- non-small-cell lung carcinoma
- Manufacturer
- Nuvation
- FDA application
- NDA219713
Drug class
How this class works, per Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf.
May treat (source: NIH RxClass)
See how Ibtrozi ranks — best-rated kinase inhibitor for:
Dosage forms
Capsule
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Ibtrozi treat?
- Ibtrozi (Taletrectinib Adipate) may be used to treat non-small-cell lung carcinoma, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How does Ibtrozi work?
- Ibtrozi is a kinase inhibitor. Kinase inhibitors block protein kinases, the enzymes that relay 'grow and divide' signals inside cells. By shutting down the overactive kinase signals that a tumor depends on, they help slow or stop cancer cells from multiplying.
- Is there a coupon or discount for Ibtrozi?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Ibtrozi. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Ibtrozi?
- Ibtrozi is marketed by Nuvation. You can see Nuvation's full profile, rating, and other products on pharmaranks.
- Is Ibtrozi a brand-name or generic drug?
- Ibtrozi is a brand-name product with the active ingredient Taletrectinib Adipate.
- Is Ibtrozi available over the counter?
- No. Ibtrozi is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Ibtrozi come in?
- Ibtrozi is currently marketed as capsule, per the FDA's National Drug Code Directory.
- What class of drug is Ibtrozi?
- Ibtrozi is classified as kinase inhibitor, per the FDA's Established Pharmacologic Class.
- Is Ibtrozi FDA-registered?
- Ibtrozi is on record with the U.S. FDA under application number NDA219713. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about TALETRECTINIB ADIPATE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 7 reports naming TALETRECTINIB ADIPATE — the active ingredient in Ibtrozi, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- diarrhoea2 reports
- pyrexia2 reports
- vomiting2 reports
- blindness transient1 reports
- brain neoplasm malignant1 reports
- degenerative bone disease1 reports
- drug eruption1 reports
- erythema1 reports
Read these as a signal, not a rate. A report does not mean TALETRECTINIB ADIPATE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
danziten
Nilotinib Tartrate
everolimus
Everolimus
ofev
Nintedanib Esylate
sprycel
Dasatinib
afinitor
Everolimus
calquence
Acalabrutinib
Compare Ibtrozi head-to-head
More kinase inhibitor drugs
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
ibtrozi
New